{
  "ticker": "CD3",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02978046",
  "id": "02978046",
  "pages": 8,
  "price_sensitive": false,
  "date": "20250807",
  "time": "1443",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250807/pdf/06mmz2pbk9gs30.pdf",
  "summary": "### **Quarterly Report (Appendix 4C) Summary \u2013 CD Private Equity Fund III (ASX: CD3)**  \n\n#### **Key Financial & Operational Highlights:**  \n- **NTA per unit (post-tax):** $1.81 (down from $1.87 in Q1 2025 due to FX losses).  \n- **Quarterly NTA return:** -3.2% (attributed to AUD strengthening).  \n- **Fund cash balance:** A$9.38m + US$6.85m (LP cash) = **~A$19.8m total liquidity** (AUD:USD 0.6581).  \n- **Portfolio realisations (Q2):**  \n  - Realised **U.S. Urology Partners** (NMS Fund III) \u2013 Gross MOIC: **2.0x**.  \n  - Median Gross MOIC on historical realisations: **2.8x**.  \n- **Remaining portfolio:** 60 active companies (48 earners, 12 impaired but holding value).  \n- **Potential capital return:** Management assessing excess capital distribution to CD3 unitholders (follows CD2\u2019s $0.12/unit off-cycle distribution).  \n\n#### **Market Context:**  \n- **Challenges:** Rising tariffs, high rates, and geopolitical tensions slowed PE exits; 30% of firms paused deals (per PwC survey).  \n- **Secondaries market growth:** 2025 volumes forecast at **US$220bn** (vs. US$140bn in 2024).  \n\n#### **Unit Price & NTA:**  \n- **Trading discount:** Unit price **$1.17** (30 June 2025) vs. NTA $1.81 (**35.4% discount**).  \n\n---  \n*No material capital raising, M&A, or structural changes identified.*",
  "usage": {
    "prompt_tokens": 5609,
    "completion_tokens": 391,
    "total_tokens": 6000,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-07T05:14:20.223409"
}